OBJECTIVES: Patients treated for neuroendocrine tumors and acromegaly have to be periodically injected with a long-acting somatostatin analog (SSA). This study aimed at evaluating the economic implications of using a new pre-filled device for Somatuline Autogel/Depot versus Sandostatin LAR. The study was performed in three European countries and the US. METHODS: A quantitative study was performed in France, Germany, the UK and the US, including 77 nurses. The majority of nurses were from hospital wards, specialized in endocrinology and oncology. The number of SSA patients per nurse was at least 3 per year. Time spent for each injection and number of clogging episodes was recorded per nurse and per type of injection (Somatuline new device or LAR). Cost of successful injection was calculated per patient / per nurse using retail costs for the 4 countries. RESULTS: With LAR, 2 clogging incidents were reported. This led to an average of 79 injections for LAR vs. 77 for Somatuline new device. The calculated cost per successful injection for the 4 countries pooled together was in Euro: 1’603 and 1’628 respectively for Somatuline new device and LAR. The incremental cost between the 2 treatments was EUR 25 per injection. Assuming an 85% compliance, this translated up to EUR 255 per patient per year. When considering only the 3 European countries, the annual difference was EUR 724. CONCLUSIONS: The usage of a new pre-filled Somatuline device for the injection of SSA could lead to substantial savings for hospitals and health-care payers. Due to the differences in retail prices across countries, these savings could potentially be even more significant in Europe.